Dietary Iron and Recurrence of Colorectal Adenomas
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Abstract
Previous research suggests that iron acts as a prooxidant to increase the risk of colorectal
neoplasia. This study examined effects of dietary intake of iron on colorectal adenoma recurrence
using data from an antioxidant clinical trial. All subjects were free of polyps at study entry but had
at least one adenoma removed within the 3 months before enrollment. Follow-up colonoseopies
were conducted after 1 and 4 years. Patients who developed one or more adenomatous polyps
between years 1 and 4 were classified as cases; all others were controls. Dietary iron intake at
baseline and at the end of the study was estimated from self-administered food frequency
questionnalres and averaged together for each subject, enerajı-adjusted, and categorized into
quartiles. Odds ratios were adjusted for age, center, sex, calories, treatment group, and alcohol,
fiber, folate, and fat intakes in unconditional logistic regression analysis. Dietary iron was inversely
associated with adenoma risk, although risk did not decrease monotonically with increasing intake.
Odds ratios comparing second, third, and fourth quartiles to the lowest quartile were 0.61 [95%
confidence interval (CI), 0.37-1.02], 0.80 (95% CI, 0.45-1.44), and 0.37 (95% CI, 0.19-0.73),
respectively. A limited examination showed no clear evidence that use of iron supplements affected
risk of recurrence in this study population. This study provides evidence against the hypothesis
that recent dietary intake of iron increases risk for colorectal adenomas. However, these results
may reflect the presence of other dietary factors found in combination with iron.
Introduction
Considerable evidence exists for a role of oxidation in carcinogenesis, mediated primarily by
highly reactive oxygen rad-icals and free radicals that cause oxidative damage to DNA (1). It is

unclear, however, the extent to which dietary factors with presumed anti- and prooxidant activity
play a part in human cancer development. Antioxidants are thought to scavenge free radicals by
reacting with them to form less reactive products, thus protecting against oxidative damage; some
also act to help regenerate other reduced antioxidants (1). Prooxidants, on the other hand,
generate free radicals. Dietary prooxidants have received less attention than antioxidants in
epidemiological studies, but iron has been suggested as a harmful prooxidant. The prooxidant
activity of iron stems from its catalysis of the Haber-Weiss cycle of reactions in which ferric iron is
reduced but subsequently regenerated, accompanied by the formation of hydroxy radicals (2）・
Numerous studies have examined the association of iron
with colorectal neoplasia, with varying results. Indirect support for the hypothesized role of
prooxidant iron on colorectal neoplasia has come from studies showing higher risk associated
with intake of iron-rich red meat (3, 4, 5, 6). Studies on iron intake and neoplasia (7, 8,9, 10,
11, 12, 13), however, have not been consistent, although several have found an increased risk
of colorectal cancer (14, 15, 16, 17) or adenoma (18, 19) with greater iron stores and/or
intake. This report describes the association of recent dietary iron intake with colorectal adenoma recurrence using data from a multicenter antioxidant clinical trial.
Materials and Methods
Study Population. Subjects for these analyses were partici- pants in the Antioxidant Polyp
Prevention Study, a multicenter clinical trial of antioxidant supplementation. Patients were
identified between December 1984 and June 1988 from colonoscopy reports and pathology logs at
six centers: Cleveland Clinic (Cleveland, OH); Dartmouth-Hitchcock Medical Center (Lebanon, NH);
Lahey Clinic Medical Center (Burlington, MA); UCLA/Kaiser Sunset (Los Angeles, CA); the
University of Iowa (Iowa City, IA); and the University of Minnesota (Minneapolis, MN).
All eligible patients had at least one histologically con-firmed adenoma removed within
the 3 months before study entry and were judged to be恥e of further polyps based on
complete colonoscopy prior to enrollment. Subjects also had to be in good health and under
80 years old. Patients were excluded if they had familial polyposis, a history of invas-ive
colorectal cancer, any malabsorption syndrome, or any conditions that might be worsened by
vitamin C or E supplementation.
Participants in the clinical trial gave informed consent and were randomly assigned using a
two-by-two factorial design to four treatment groups：β-carotene plus placebo, vitamins C and E
plus placebo, β-carotene plus vitamins C and E, and placebo only. Two complete follow-up

colonoscopies were conducted approximately 1 and 4 years after the qualifying cobonoscopy. At
these follow-up exams, the size and location of any raised mucosal lesions were recorded, all
lesions were excised, and microscopical slides were sent for review to the study pathologist for
classification as either neoplastic (adenoma) or nonneoplastic (hyperplastic polyp, lymphoid
follicle, or other type of lesion). For these analyses, patients found to have one or more
adenomatous pobyps during the interval after the 1-year exam up to and including the 4-year exam
were classified as cases, whereas those without adenomatous polyps were classifled as controls.
Data Collection. Information on diet was collected using the Health Habits and History
Questionnaire, a semiquantitative food frequency questionnaire developed at the National Cancer
Institute (20). The questionnaire was self-administered and was given to patients twice: once
before randomization, then again at the end of the study. Each time, subjects reported their intake
of over 100 foods believed to contribute importantly to the intake of calories and 17 macro- and
micronutrients in the national diet (21, 22). For each food item, subjects estimate their frequency of
intake over the previous year and whether their usual portion size was small, medium, or large.
Average nutrient intakes per day at baseline and at the end of the study were then calculated based
on portion size, nutrient content, and frequency of consumption of each food using the Dietary
Analysis System developed for use with the Health Habits and History Questionnaire. Patients were
excluded from analysis if their responses to the questionnaire were deemed unreliable: specifically,
if they reported eating fewer than three foods a day, skipped more than 50 foods in the
questionnaire, or reported daily caloric intake less than 500 or greater than 5000 kcals. These
calculations included intake from dietary sources only and did not include nutrients derived from
supplements. In addition, because red meat may be a proxy for bioavailabbe iron and has been
associated with increased risk in previous studies, a variable representing weekly frequency of red
meat consumption was created based on reported consumption of hamburger, beef, beef stew,
pork, veal/lamb, chili con came, and mixed dishes with meat.
Iron intake during the period of the study was estimated by averaging together mean daily
intake at baseline and at the end of the study. We chose to focus our analyses on average rather
than on baseline intake because we felt that the average would better represent intake during the
exposure period for development of pobyps. However, analyses based on baseline intake produced
results that were similar to those for the average intake.
Interval questionnaires were sent to patients every 6 months during the trial and elicited
information on their compliance with the study treatment, hospitalizations, and symptoms, and use
of aspirin and various nutritional supplements. Other detailed information on supplement intake

was obtained from a self-administered questionnaire given at enrollment, in which patients were
asked whether they had ever taken various vitamin or mineral supplements, how long they had
taken them, and their last year of use.

Data Analysis. Average nutrient intakes were energy-adjusted using the linear regression
techniques of Wiblett and Stampfer (23) and were categorized into quartiles; ORs3 were calculated
relative to the lowest quartile. We used unconditional logistic regression to estimate ORs and 95%
CI, adjusting for potential confounders. Covariates included age, sex, center, treatment group,
caloric intake, and energy-adjusted intakes of alcohol, fiber, folate, and total fat, with alcohol, fiber,
fobate, and fat intakes categorized into quartiles. We also considered number of months between
the 1-year and 4-year follow-up cobonoscopies, body mass index, aspirin, any vitamin or mineral
supplement use during the study, and family history of coborectal cancer as potential confounders.
However, because removing them from the model did not substantially change parameter
estimates for any of the nutrients of interest, results are presented for models not including these
covariates. We classified individuals as users of aspirin during the study if they reported taking
aspirin on at least 50% of their returned interval questionnaires. Use of any vitamin or mineral
supplements during the study was defined similarly. Average number of servings of red meat per
week was also categorized into quartiles, with ORs calculated relative to the lowest quartile and
adjusted for the same covariates.
To test for linear trend, we included a variable representing the scaled median value for
each quartile of residual intake into the mubtivariate model, including the same covariates listed
above. The effects of dietary iron did not appear to differ between those receiving either study
treatment (either vitamin C and E supplementation or (β-carotene supplementation). Therefore,
results are presented for all study participants combined.
To examine the association between iron supplement use and adenoma recurrence,
individuals were classified as users of iron supplements if they reported taking them at baseline
and if their reported last year of use was the same year that they completed the questionnaire.
Individuals were also classified based on length of use of iron supplements at any time before the
study. Because of the small number of iron supplement users, ORs were estimated relative to
nonusers by including the variable in a logistic regression model adjusted only for age and center.
Results

Data were reviewed for 2029 potentially eligible patients, of whom 387 were found to be ineligible
for the trial, 502 refused participation, 152 could not be contacted, and 7 did not enroll in the
clinical trial for unknown reasons. The remaining 981 agreed to participate, and 864 were actually
randomized. Ultimateby, 751 of these underwent both follow-up cobonoscopies, and 666 provided
satisfactory data on both dietary questionnaires.
Characteristics of the 247 cases and 419 controls were generally comparable with respect
to age, race, education, body mass index, current smoking status, and family history of colon cancer
(Table 1). A slightly larger proportion of cases were males, whereas controls tended to have fewer
prior adenomas and were more likely to use aspirin and to take vitamin or mineral supplements
during the period of study.
Contrary to expectation, dietary iron had a strong inverse association with adenoma
recurrence, although ORs did not decrease monotonically with increasing iron intake (Table 2). OR
comparing second and third quartiles to the lowest quartile were 0.58 (95% CI, 0.35-0.95) and 0.77
(95% CI, 0.44-1.33), respectively. Patients in the highest quartile of energy-adjusted iron intake
were about one-third as likely to develop adenomas as those in the lowest quartile (OR, 0.35; 95%
CI, 0.19-0.66). Red meat intake, on the other hand, showed little association with adenoma
recurrence; after adjustment for other covariates, the OR comparing highest to lowest quartiles of
weekly red meat intake was 1.26 (95% CI, 0.72-2.21).
We also examined the association between adenoma recurrence and use of iron
supplements prior to the study. The OR for adenoma recurrence for use of iron supplements at
baseline relative to nonuse was 1.65 (95% CI, 0.68-4.03). However, the estimate was based on only
21 individuals reporting iron supplement use at baseline. Furthermore, 8 of the 21 reported using
iron supplements for only 1 year. When patients were categorized based on their length of use of
iron supplements, the OR for using iron supplements regularly for 2 years or more at any time
before the study was 1.25 (95% CI, 0.58-2.68).
Discussion
Results from these analyses provide no support for the hypothesis that dietary iron increases risk
of adenoma recurrence. Indeed, dietary iron was inversely associated with risk. The use of iron
supplements prior to the study or at baseline appeared to be positively associated with recurrence
of adenomas, although estimates were based on small numbers and did not reach conventional
levels of statistical significance.

Several case-control studies have also found no association or even a slightly inverse
association between dietary iron and coborectab adenomas (7, 8, 9, 10). In contrast, most studies of
invasive coborectab cancer risk (11, 14, 15, 17), but not all (13), have suggested a positive
association with iron intake. Research based on biochemical indicators of iron status, however,
have consistently found a positive association between elevated iron status and either coborectal
adenomas (18, 19) or cancer (14, 15, 16).
The discrepancy between findings based on biochemical, as opposed to dietary, measures of
iron status suggest that the two are not equivalent indicators of iron exposure. For example, a high
intake of iron may not increase risk if the consumed iron is either not absorbed or not bioavaibable
in the lumen. Iron in foods may have bow bioavaibability, limiting its ability to catalyze free radicalgenerating reactions. Graf and Eaton (24) has suggested that compounds in dietary fiber, such as
phytic acid, can chelate iron, thus inhibiting the production of hydroxy radicals.
In our study population, iron intake was strongly correbated with intake of dietary fiber
(Pearson’s r = 0.70) but not with intake of red meat (Pearson’s r 0.24). This suggests that the major
contributors to total iron intake were plant sources such as cereals and grains, rather than red
meat, and that iron bioavailabibity in our study population was bow. Indeed, the level of red meat
intake in this population was fairly low overall; mean frequency of red meat intake ranged from 0.2
servings per week in the lowest quartile to 1.4 servings per week in the highest quartile. The
generally low intake of red meat in this population may explain why we found little association
between red meat and adenoma recurrence, whereas others have found an association of red meat
with coborectal adenomas (3-5) or coborectal cancer (6).
In a case-control study on iron and coborectab adenomas conducted by Bird et al. (19), total
iron intake, including iron from both the diet and supplements, was positively associated with
adenomas. However, the positive association disappeared when the analyses were focused on iron
from food only, leading the authors of the study to suggest that iron increases risk primarily when
consumed in supplements: apart from the regular diet and in barge doses. In contrast, Tseng et al.
(1 1) found no association between total iron intake and colorectal adenomas after adjustment for
other micronutrients. Our data mdicated that use of iron supplements at baseline, or use for at
beast two years before enrollment, was slightly (and nonsignificantly) associated with adenoma
recurrence. However, very few patients reported using iron supplements at enrollment, and almost
one-half of all ever-users of iron supplements had taken them for only 1 year. Also, no information
was available on the regularity or doses of supplement use. Nevertheless, in bight of our findings

and others’ (19), diet- and supplement-derived iron may most usefully be analyzed separately in
future research.
The association between dietary iron and recurrence of adenomas in this study may have
been confounded by other dietary or lifestyle factors. For example, the high correlation with fiber
intake suggests that iron may have been consumed with other components in the diet that exerted a
protective effect in this population. Certainly, the effects of individual nutrients are not easily
isolated in any observational analysis, especially in the presence of numerous other correlated
dietary factors. Iron may also interact with other dietary factors, cxerting different effects
depending on the other nutrients with which it is consumed.
An alternative explanation for our findings is that symptoms caused some patients to
change their dietary habits during the study, for example, by limiting their meat consumption.
However, adenomas are generally asymptomatic. Also, comparison of changes in iron intake
between baseline and at the end of the study indicated that mean iron intake increased similarly in
cases and controls, from 13.7 to 14.8 mg/days in cases and from 15.0 to 15.7 mg/days in controls.
In addition, when analyses were based on intake measured at baseline only, results were similar.
Although we chose to examine the effects of usual dietary intake during the study period, it
is also possible that earlier dietary habits are of greater etiobogical interest than recent diet, and
that recent intake has little or no effect on polyp development or growth. If individuals at higher
risk for adenoma recurrence were more likely to change their diets in response to their initial
adenoma diagnosis, this could have led to lower intake of iron in the case population during the
period of study, resulting in a misleading association between iron and adenoma recurrence.
However, when we stratified on number of prior adenomas, we found no evidence that the
observed association between iron and adenoma recurrence was the result of bias due to dietary
change in those at presumably higher risk of recurrence, i.e., those with a larger number of prior
adenomas. Furthermore, for the majority of patients, even those with more than one prior
adenoma, the qualifying exam was their first adenoma experience, thus also reducing the potential
for bias. It should also be noted that the most appropriate time period for which to collect
information on dietary intake is not known; at the very least, these analyses offer findings regarding
shortterm, recent intake of iron; the effects of long-term or more distant past intake warrant
further investigation.
Findings from this study may be of limited generalizability, because participants in the
intervention trial represent a highly selected group of individuals. For example, because only
individuals with prior adenomas were eligible for participation in the trial, findings from the study

relate only to risk of adenoma recurrence; risk factors for a first adenoma may be different.
However, a strength of this study is that complete cobonoscopies were performed for all study
participants according to a uniform schedule, confirming the absence of adenomas in the control
population and reducing misclassification of disease status. Using a uniform schedule for follow-up
exams for all patients, thus avoiding incidental diagnoses, helped minimize the potential for biased
detection of polyps.
Results from these analyses show an inverse association between recent dietary intake of
iron and recurrence of adenomas. A limited examination showed no clear evidence that use of iron
supplements affected risk of recurrence in this study population. Possible differences in effect
between dietary and supplemental iron, measurement of iron intake incorporating information on
bioavailability, and the effect of dietary iron intake from the more distant past are all issues that
warrant attention in future studies. Food-bevel analyses and examination of dietary patterns may
also prove to be more informative and more appropriate than nutrient-level analyses for purposes
of intervention and prevention. Whatever approach is used, however, providing information that
can be used practically for intervention remains an important objective for continued work in this
area.
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